TCTR20171111002Enrolling By Invitation2 期
Efficacy of Phlai capsule and loratadine as treatment in allergic rhinitis patients
Thai Traditional Medical Knowledge Fund0 个研究点目标入组 75 人开始时间: 2017年11月11日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- Enrolling By Invitation
- 发起方
- 入组人数
- 75
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 50 Years（—）
- 性别
- All
入选标准
- •1.age between 18-50 years old
- •2. Diagnose of allergic rhinitis (at least mild intermittent)
- •3. Daily Total nasal symptoms score 6-10 on 3 consecutive day
- •4. Skin test positive at least one from five aeroallergen (house dust mite, cockroach, cat hair, dog dander, Bermuda grass)
- •5. Do not use
- •- Intradermal nasal steroid 2 week
- •- Systemic corticosteroid 2 week
- •- Antihistamine 1 week
- •- Intranasal or systemic decongestant 3 day
- •6. No smoking
- •7. No alcohol use
- •8. No allergic history to herb
排除标准
- •1. Have chronic illness or underlying disease (heart is ease, renal disease ,liver disease)
- •2. During on immunotherapy for allergic rhinitis treatment
- •3.Asthmatic patient
- •4.Take antidepressant, sedative ,anxiolytics, opioids, neuroleptic drug
- •5. After intranasal surgery within 6 months
- •6. Nasal polyp, nasal septum deviation, acute or chronic rhinosinusitis
- •7. Pregnancy or lactation
研究者
相似试验
招募中
3 期
oratadine and Diabetic nephropathyIRCT20201014049027N1Shiraz University of Medical Sciences80
已完成
3 期
Effectiveness of Two Preparations of Loratadine + Pseudoephedrine in Patients With Perennial Allergic Rhinitis.Perennial Allergic RhinitisNCT01228630Azidus Brasil156
已完成
3 期
The efficacy and safety of liraglutide as adjunct therapy to insulin in the treatment of type 1 diabetes; A 52-week randomised, treat-to-target, placebo-controlled, double-blinded, parallelgroup, multinational, multi-centre trial10018424diabetesNL-OMON38605ovo Nordisk50
进行中（未招募）
1 期
The efficacy and safety of liraglutide as adjunct therapy to insulin in the treatment of type 1 diabetesDiabetes Mellitus, Type 1MedDRA version: 16.0Level: LLTClassification code 10045228Term: Type I diabetes mellitusSystem Organ Class: 100000004861EUCTR2012-003580-21-NOovo Nordisk A/S1,398
进行中（未招募）
不适用
The efficacy and safety of liraglutide as adjunct therapy to insulin in the treatment of type 1 diabetesDiabetes Mellitus, Type 1MedDRA version: 16.1Level: LLTClassification code 10045228Term: Type I diabetes mellitusSystem Organ Class: 100000004861EUCTR2012-003580-21-SEovo Nordisk A/S1,404